3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer - Contacts and Locations

3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

This study has been completed.

Study NCT00064051. Last updated on August 23, 2008. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00064051

Locations


United States, Illinois
	University of Chicago Cancer Research Center
	Chicago, Illinois, United States, 60637-1470

United States, Indiana
	Indiana Oncology Hematology Consultants
	Indianapolis, Indiana, United States, 46202

United States, Minnesota
	University of Minnesota Cancer Center
	Minneapolis, Minnesota, United States, 55455

United States, Tennessee
	Sarah Cannon Cancer Center at Centennial Medical Center
	Nashville, Tennessee, United States, 37203

Belgium
	Universitair Ziekenhuis Gent
	Ghent, Belgium, B-9000

United Kingdom, England
	Christie Hospital N.H.S. Trust
	Manchester, England, United Kingdom, M20 4BX
	Royal Marsden NHS Foundation Trust - Surrey
	Sutton, England, United Kingdom, SM2 5PT

Sponsors and Collaborators

Vion Pharmaceuticals

Investigators


Study Chair:	Mario Sznol, MD	Vion Pharmaceuticals